Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

Study About the Safety of Soticlestat and if it can Help Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome who Have Alread… Ended

2023-504104-29-00 Dravet Syndrome/Lennox-Gastaut Syndrome 5 2024-04-15
MK-4318 CIDF Target Engagement Study Ended

2023-509645-12-00 Pain 3 2024-04-12
A phase 1, open-label, cross-over study in healthy volunteers to assess the pharmacokinetic profile of Prazosin and Cyproheptadine following… Ended

2023-507788-20-00 alcohol use disorder 1 2024-04-11
RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 M… Ended

2023-508747-49-00 Antimigraine 2 2024-04-10
Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102 Ended

2023-503729-20-00 Alzheimer’s Disease 3 2024-03-27
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults Ended

2023-508814-40-00 Neurological and neuropsychiatric conditions 3 2024-03-11
A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Latera… Ended

2023-506509-21-00 Amyotrophic Lateral Sclerosis 3 2024-03-08
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Ended

2023-506127-29-00 Diabetic Peripheral Neuropathy 4 2024-03-05
An open-label sleep laboratory study of efficacy and safety of piromelatine in patients with idiopathic Rapid Eye Movement Behavior Disorder… Ended

2023-506713-22-00 idiopathic (isolated) Rapid Eye Movement Behavior Disor 4 2024-03-05
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Ended

2022-502713-29-00 Dyskinesia due to cerebral palsy (DCP) 5 2024-03-01
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
Bioequivalence of Cladribine 10 mg from two different products Ended

2023-508656-19-00 No therapeutic indication in the current trial with hea 2 2024-03-01
A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokine… Ended

2023-509862-39-00 Healthy volunteers 2 2024-02-23
A study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Ph… Ended

2023-508382-33-01 Proteinopathies 3 2024-02-22
The TAF-MS study Ended

2023-503814-62-00 Multiple sclerosis 4 2024-02-06
Testing for the first time the effects of a new medicine in healthy people Ended

2023-507880-20-00 Psychatric disorder 1 2024-02-05
Treating Leg Symptoms in Woman with X-ALD Ended

2024-518989-27-01 X-linked adrenoleukodystrophy 6 2024-02-04
Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics of PBFT02 in Adult Participants with Frontotemporal Dementia (FTD) an… Ended

2023-507724-23-00 FRONTOTEMPORAL DEMENTIA (FTD) 7 2024-02-01
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy… Ended

2023-505241-10-00 Huntington's disease 4 2024-01-30
A study in healthy people to test whether iclepertin has an effect on cardiac safety Ended

2023-504693-38-00 Healthy 3 2024-01-25
Phase 0 lead-in trial of Pitavastatin in primary and recurrent Glioblastoma patients Ended

2023-505743-38-00 Glioblastoma Multiforme 3 2024-01-18
Study on the investigational drug IAMA-6, placebo-controlled, administered to healthy adult volunteers, at single oral doses and at multiple… Ended

2023-507454-33-00 Neurodevelopmental disorder 1 2024-01-08
Pilot study of safety and efficacy of nicotinamide (vitamin B3) in OPA1 Dominant Optic Atrophy - NICOPA1-TOL Ended

2023-506214-52-00 Dominant Optic Atrophy 5 2023-12-27
[18F]-Fludarabine PET/MR Imaging for the Assessment of Newly-diagnosed Primary Central Nervous System (CNS) Lymphoma : a Pilot PET-MRI Study Ended

2024-512758-62-00 Patients with newly diagnosed primary central nervous s 9 2023-12-18